Medicus Pharma: Targeting Urinary Retention with a Novel Non-Invasive Therapy
Medicus Pharma is introducing a groundbreaking therapy to prevent relapse in men suffering from acute urinary retention due to enlarged prostate.
Advancing prostate health with innovation backed by proven biotech pioneers
Every year, nearly 1 million men in the U.S. face the sudden and painful onset of acute urinary retention (AUR)—a medical emergency that often leads to repeat ER visits. Medicus Pharma, known for developing the revolutionary skin cancer patch, is now addressing this urgent need with a non-invasive therapy designed to prevent relapse.
Targeting a $2 billion market, Medicus Pharma’s solution could change how prostate-related emergencies are managed, offering relief and reducing the likelihood of recurrence. With a legacy of biotech innovation and a clear clinical focus, Medicus is advancing a therapy that meets an immediate and recurring need for millions.
To learn more about Medicus Pharma (NASDAQ: MDCX), watch their video HERE
Published by BTV - The Agency
Discover Investment Opportunities with BTV. Delivering engaging content to Investors for 25+ years.
You might also like
HIVE Digital Technologies: Building the Future with Bitcoin and AI
HIVE Digital Technologies (TSX.V: HIVE, NASDAQ: HIVE) isn’t just mining Bitcoin—it’s powering the next era of high-performance computing. With a strong focus on sustainability and AI infrastructure, HIVE is executing on two transformative trends at once.
Bitcoin Well: Replacing the Bank, One Bitcoin at a Time
Bitcoin Well (TSXV: BTCW, OTCQB: BCNWF) is redefining what it means to be your own bank. With a unique blend of Bitcoin financial services and a strategic treasury reserve, the company is helping individuals transition away from traditional banking systems.